AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14564615 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 34
Study 14564615 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 34
Study 8930036 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled oesophagogastric anastomosis
Number of subjects: 100
Study 8930036 — intervention group
Group type: COMPARATOR
Intervention: Handsewn oesophagogastric anastomosis
Number of subjects: 100
Study 1873002 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 g/day SF
Number of subjects: 62
Study 1873002 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 g/day SF
Number of subjects: 62
Study 1873002 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g/day SF
Number of subjects: 62
Study 1873002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 1873002 — intervention group
Group type: EXPERIMENTAL
Intervention: All three SF doses
Number of subjects: 62
Study 1873002 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-sensitive patients
Number of subjects: 62
Study 1873002 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-insensitive patients
Number of subjects: 62
Study 1873002 — intervention group
Group type: EXPERIMENTAL
Intervention: Seaweed preparation
Number of subjects: 62
Study 6126067 — intervention group
Group type: EXPERIMENTAL
Intervention: Estazolam (1 + 1 + 4 mg)
Number of subjects: 58
Study 6126067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 2859069 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 36
Study 2859069 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam
Number of subjects: 36
Study 2859069 — intervention group
Group type: COMPARATOR
Intervention: Control period
Number of subjects: 36
Study 31897941 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (50 ml per day for 10 days, followed by two additional treatment cycles with 10 ml per day for 10 days)
Number of subjects: 142
Study 31897941 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline solution (placebo)
Number of subjects: 142
Study 29551172 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate (50 mg capsules, three times daily for 14 days)
Number of subjects: 0
Study 29551172 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules (three times daily for 14 days)
Number of subjects: 0
Study 29551172 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate
Number of subjects: 0
Study 26669919 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 160 mg administered at weeks 16, 18, and 20, then every 4 weeks through Week 64
Number of subjects: 390
Study 26669919 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab treatment
Number of subjects: 390
Study 24754961 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual training in a structured multimodality training curriculum
Number of subjects: 100
Study 24754961 — intervention group
Group type: EXPERIMENTAL
Intervention: Pair training in a structured multimodality training curriculum
Number of subjects: 100
Study 24754961 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training between tests)
Number of subjects: 100
Study 24754961 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual training
Number of subjects: 100
Study 24754961 — intervention group
Group type: EXPERIMENTAL
Intervention: Pair training
Number of subjects: 100
Study 24754961 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive tests and questionnaires
Number of subjects: 100
Study 23778432 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion (when initial hemoglobin > 10 g/dL)
Number of subjects: 1158
Study 20400258 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis school programme (four classes of 8‐12 participants over four weeks)
Number of subjects: 300
Study 20400258 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study 20400258 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis school programme
Number of subjects: 300
Study 18082007 — intervention group
Group type: EXPERIMENTAL
Intervention: PALS program (intervention group)
Number of subjects: 14
Study 18082007 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed intervention)
Number of subjects: 14
Study 15871011 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPSV
Number of subjects: 36
Study 15871011 — intervention group
Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 36
Study 12764217 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction surgery
Number of subjects: 2231
Study 12764217 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 2231
Study 12764217 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight change (both groups)
Number of subjects: 2231
Study 11016286 — intervention group
Group type: EXPERIMENTAL
Intervention: Active laser treatment (50 mW, 830 nm, 10 minutes per session)
Number of subjects: 49
Study 11016286 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 49
Study 8851530 — intervention group
Group type: EXPERIMENTAL
Intervention: Water temperature of 30 degrees C
Number of subjects: 6
Study 8851530 — intervention group
Group type: EXPERIMENTAL
Intervention: Water temperature of 38 degrees C
Number of subjects: 6
Study 8851530 — intervention group
Group type: COMPARATOR
Intervention: No water in the bath tub (control)
Number of subjects: 6
Study 1485782 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium alginate (alginic acid)
Number of subjects: 76
Study 6691244 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (5 micrograms/kg/min intravenously)
Number of subjects: 20
Study 6691244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31571834 — intervention group
Group type: EXPERIMENTAL
Intervention: Test FDC tablet containing 10 mg melitracen and 0.5 mg flupentixol
Number of subjects: 48
Study 31571834 — intervention group
Group type: COMPARATOR
Intervention: Reference FDC tablet containing 10 mg melitracen and 0.5 mg flupentixol
Number of subjects: 48
Study 30376823 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly cell phone counselling and daily text messages
Number of subjects: 1036
Study 30376823 — intervention group
Group type: COMPARATOR
Intervention: Routine healthcare services
Number of subjects: 1036
Study 27401319 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIT with probiotic
Number of subjects: 100
Study 27401319 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIT with vitamin D
Number of subjects: 100
Study 27401319 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIT alone
Number of subjects: 100
Study 27401319 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SLIT)
Number of subjects: 100
Study 25271822 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamphetamine sulfate (0.3 mg/kg) administered intravenously
Number of subjects: 38
Study 25271822 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 38
Study 22119172 — intervention group
Group type: EXPERIMENTAL
Intervention: Free delayed recall after 4 weeks
Number of subjects: 73
Study 22119172 — intervention group
Group type: EXPERIMENTAL
Intervention: Free delayed recall after 1 week
Number of subjects: 73
Study 22119172 — intervention group
Group type: COMPARATOR
Intervention: Standard 30-min retention interval
Number of subjects: 73
Study 22119172 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory (BDI) assessment
Number of subjects: 73
Study 20149145 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention (EI) consisting of seven in-hospital sessions prior to discharge and four home visits.
Number of subjects: 146
Study 20149145 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - no specific intervention mentioned.
Number of subjects: 146
Study 20149145 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention (EI)
Number of subjects: 146
Study 17968992 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (2 mg/kg/day in 3 divided doses for 3 days)
Number of subjects: 266
Study 17968992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study 16221106 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan plus conventional therapy (CT)
Number of subjects: 0
Study 16221106 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (CT) alone
Number of subjects: 0
Study 16221106 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan plus CT
Number of subjects: 0
Study 12602521 — intervention group
Group type: COMPARATOR
Intervention: Oral and parenteral L-ornithine-L-aspartate (OA)
Number of subjects: 0
Study 12602521 — intervention group
Group type: COMPARATOR
Intervention: Oral L-ornithine-L-aspartate (OA)
Number of subjects: 0
Study 12602521 — intervention group
Group type: COMPARATOR
Intervention: Intravenous L-ornithine-L-aspartate (OA)
Number of subjects: 0
Study 9531901 — intervention group
Group type: COMPARATOR
Intervention: Conventional method (group I, n=29)
Number of subjects: 95
Study 9531901 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified technique (group II, n=30)
Number of subjects: 95
Study 9531901 — intervention group
Group type: COMPARATOR
Intervention: Control group (group III, n=29)
Number of subjects: 95
Study 7647144 — intervention group
Group type: EXPERIMENTAL
Intervention: Prifinium bromide
Number of subjects: 30
Study 7647144 — intervention group
Group type: COMPARATOR
Intervention: Hyoscine N-butylbromide
Number of subjects: 30
Study 2491458 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg omeprazole daily
Number of subjects: 171
Study 2491458 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole daily
Number of subjects: 171
Study 590310 — intervention group
Group type: EXPERIMENTAL
Intervention: 14C‐aminopyrine 9 mg/kg (pharmacological dose)
Number of subjects: 9
Study 590310 — intervention group
Group type: COMPARATOR
Intervention: Tracer amount of 14C‐aminopyrine
Number of subjects: 9
Study 30842115 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 30 mg
Number of subjects: 60
Study 30842115 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg
Number of subjects: 60
Study 30842115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28220512 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir-voxilaprevir alone
Number of subjects: 49
Study 28220512 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir-voxilaprevir with ribavirin
Number of subjects: 49
Study 25989213 — intervention group
Group type: EXPERIMENTAL
Intervention: Forsus Fatigue Resistant Device (FFRD) alone
Number of subjects: 43
Study 25989213 — intervention group
Group type: EXPERIMENTAL
Intervention: Forsus Fatigue Resistant Device (FFRD) and mini-implants (FMI)
Number of subjects: 43
Study 25989213 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 43
Study 24355657 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent powder (EP)
Number of subjects: 92
Study 24355657 — intervention group
Group type: COMPARATOR
Intervention: No effervescent powder (non-EP)
Number of subjects: 92
Study 22743148 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 25 mg/m²
Number of subjects: 90
Study 22743148 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone 12 mg/m²
Number of subjects: 90
Study 19627577 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate medication use (long-acting benzodiazepines)
Number of subjects: 6343
Study 19627577 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate medication use (other inappropriate psychotropics)
Number of subjects: 6343
Study 19627577 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate medication use (medications with anticholinergic properties)
Number of subjects: 6343
Study 19627577 — intervention group
Group type: EXPERIMENTAL
Intervention: Occasional or regular use of short- or intermediate-acting benzodiazepines
Number of subjects: 6343
Study 19627577 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting benzodiazepines
Number of subjects: 6343
Study 17560254 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine oral calcitriol and calcium carbonate postoperatively (Group 1)
Number of subjects: 86
Study 17560254 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate postoperatively at the discretion of the primary surgeon (Group 2)
Number of subjects: 86
Study 15277163 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (Bic)
Number of subjects: 11
Study 15277163 — intervention group
Group type: COMPARATOR
Intervention: Sodium lactate (Lac)
Number of subjects: 11
Study 11555433 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated bednets
Number of subjects: 1961
Study 11555433 — intervention group
Group type: COMPARATOR
Intervention: No net (control group)
Number of subjects: 1961
Study 9331015 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8‐16 mg once‐daily
Number of subjects: 350
Study 9331015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 8176802 — intervention group
Group type: EXPERIMENTAL
Intervention: Active compression-decompression CPR (ACD CPR)
Number of subjects: 130
Study 8176802 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 130
Study 3319731 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical minoxidil 2%
Number of subjects: 225
Study 3319731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 3319731 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical minoxidil 2% and Placebo
Number of subjects: 225
Study 29800250 — intervention group
Group type: EXPERIMENTAL
Intervention: LV rehabilitation (low-vision devices with therapy)
Number of subjects: 323
Study 29800250 — intervention group
Group type: COMPARATOR
Intervention: Basic LV services (low-vision devices without therapy)
Number of subjects: 323
Study 29800250 — intervention group
Group type: EXPERIMENTAL
Intervention: LV rehabilitation
Number of subjects: 323
Study 25529391 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 week rehabilitation programme including cancer-related education, progressive muscle relaxation, and emotional support
Number of subjects: 47
Study 25529391 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 47
Study 24530385 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen tape
Number of subjects: 0
Study 24530385 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen gel
Number of subjects: 0
Study 24530385 — intervention group
Group type: COMPARATOR
Intervention: Control (shower after application)
Number of subjects: 0
Study 22854954 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track surgery (FTS) + laparoscopy-assisted radical distal gastrectomy (LADG)
Number of subjects: 88
Study 22854954 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopy-assisted radical distal gastrectomy (LADG)
Number of subjects: 88
Study 22854954 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track surgery (FTS) + open distal gastrectomy (ODG)
Number of subjects: 88
Study 22854954 — intervention group
Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 88
Study 20332484 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus 5-fluorouracil (5-FU)-based adjuvant chemotherapy
Number of subjects: 1389
Study 20332484 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1389
Study 17070962 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (50mg/m² i.v.) plus Gemcitabine (1250mg/m² i.v.)
Number of subjects: 154
Study 17070962 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (50mg/m² i.v.) plus Gemcitabine (1250mg/m² i.v.) plus Vinorelbine (25mg/m² i.v.)
Number of subjects: 154
Study 15806211 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal budesonide (BUD) 200 microg twice daily
Number of subjects: 60
Study 15806211 — intervention group
Group type: COMPARATOR
Intervention: Oral choline (tricholine citrate, TRI) 500 mg thrice daily
Number of subjects: 60
Study 12542101 — intervention group
Group type: EXPERIMENTAL
Intervention: 16% carbamide peroxide
Number of subjects: 20
Study 12542101 — intervention group
Group type: COMPARATOR
Intervention: 10% carbamide peroxide
Number of subjects: 20
Study 12542101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7822663 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0591 (3 oral doses of 250 mg each at 24, 12, and 1.5 hours before allergen inhalation)
Number of subjects: 8
Study 7822663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2793717 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic alkalosis induced by oral administration of NaHCO3
Number of subjects: 8
Study 2793717 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 8
Study 33495 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepin
Number of subjects: 28
Study 33495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 31033610 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training
Number of subjects: 138
Study 31033610 — intervention group
Group type: EXPERIMENTAL
Intervention: ESWT plus eccentric training
Number of subjects: 138
Study 31033610 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shockwave therapy (ESWT)
Number of subjects: 138
Study 31033610 — intervention group
Group type: COMPARATOR
Intervention: Topical glyceryl trinitrate patch plus eccentric training
Number of subjects: 138
Study 31033610 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 138
Study 29060739 — intervention group
Group type: EXPERIMENTAL
Intervention: Game-assisted therapy and conventional therapy
Number of subjects: 13
Study 29060739 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 13
Study 27405749 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (posttetanic count of 1 or 2)
Number of subjects: 64
Study 27405749 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade (train-of-four count of 1 or 2)
Number of subjects: 64
Study 23271794 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 110 mg BID
Number of subjects: 18113
Study 23271794 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg BID
Number of subjects: 18113
Study 23271794 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant use of a single antiplatelet
Number of subjects: 18113
Study 23271794 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet
Number of subjects: 18113
Study 20705951 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV/r (400mg/100mg) + BILR 355 (150 mg)
Number of subjects: 34
Study 20705951 — intervention group
Group type: COMPARATOR
Intervention: BILR 355/r (150 mg/100mg)
Number of subjects: 34
Study 19164988 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial nasal bone reduction
Number of subjects: 330
Study 19164988 — intervention group
Group type: COMPARATOR
Intervention: Classic nasal bone reduction
Number of subjects: 330
Study 17958625 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin (50 mg/kg per day)
Number of subjects: 132
Study 17958625 — intervention group
Group type: COMPARATOR
Intervention: Oral erythromycin
Number of subjects: 132
Study 15636137 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial polycomponent vaccine (VP‐4)
Number of subjects: 30
Study 15636137 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 30
Study 11452163 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously frozen RBCs stored at 4 degrees C in AS‐3 for 15 days after deglycerolization
Number of subjects: 36
Study 11452163 — intervention group
Group type: COMPARATOR
Intervention: Liquid-preserved RBCs stored at 4 degrees C in AS‐1 for 42 days
Number of subjects: 36
Study 9479761 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous condition (tone and noise gated on and off simultaneously)
Number of subjects: 6
Study 9479761 — intervention group
Group type: EXPERIMENTAL
Intervention: Asynchronous condition (tone gated on before noise)
Number of subjects: 6
Study 9479761 — intervention group
Group type: EXPERIMENTAL
Intervention: Asynchronous condition (noise gated on before tone)
Number of subjects: 6
Study 9479761 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential condition (tone offset coinciding with noise onset)
Number of subjects: 6
Study 9479761 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise-leading condition
Number of subjects: 6
Study 9479761 — intervention group
Group type: COMPARATOR
Intervention: Tone-leading condition
Number of subjects: 6
Study 8163832 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpassaged influenza B virus isolate [virus U]
Number of subjects: 62
Study 8163832 — intervention group
Group type: EXPERIMENTAL
Intervention: Passaged influenza B virus [virus P]
Number of subjects: 62
Study 8163832 — intervention group
Group type: COMPARATOR
Intervention: Uninoculated cell culture medium
Number of subjects: 62
Study 2778609 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotary electric toothbrush
Number of subjects: 40
Study 2778609 — intervention group
Group type: COMPARATOR
Intervention: Conventional toothbrushing, dental floss, and toothpicks
Number of subjects: 40
Study 4921221 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone therapy in Stage I sarcoidosis
Number of subjects: 0
Study 4921221 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil or methotrexate
Number of subjects: 0
Study 4921221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31951780 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of polygeline-free inactivated TBE vaccine (Encepur Adults, GSK) administered approximately 3 years post-primary vaccination.
Number of subjects: 0
Study 30940432 — intervention group
Group type: EXPERIMENTAL
Intervention: Photographic atlas
Number of subjects: 32
Study 26049975 — intervention group
Group type: EXPERIMENTAL
Intervention: BPS/IC group
Number of subjects: 16
Study 26049975 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 24332196 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg ivabradine
Number of subjects: 36